Program 2

Atavistik Bio's Program 2 is an oral, allosteric, AKT1-selective small molecule inhibitor being developed for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and other vascular malformations. Discovered using the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, the drug specifically targets AKT1, the primary isoform driving abnormal endothelial growth in HHT. By selectively inhibiting AKT1, the program aims to avoid the metabolic toxicities, such as hyperglycemia, typically associated with AKT2 inhibition in pan-AKT inhibitors. The program is expected to enter clinical trials in the first half of 2026.

Other names

Program 2-Atavistik Bio-AKT1-small molecule-HHT-vascular malformationsProgram2-Atavistik Bio-AKT1-small molecule-HHT-vascular malformationsProgram-2-Atavistik Bio-AKT1-small molecule-HHT-vascular malformationsAtavistik Bio AKT1 inhibitor